^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    preladenant (SCH 420814)

    i
    Other names: SCH 420814, MK-3814
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    Adenosine A2A receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Combination immunotherapy of PEG-modified Preladenant thermosensitive liposomes and PD-1 inhibitor effectively enhances the anti-tumor immune response and therapeutic effects. (PubMed, Pharm Dev Technol)
    P-pTSL has good long-term and serum stability and excellent tumor-targeting ability in mice. Moreover, the combination with PD-1 inhibitor significantly enhanced the anti-tumor effect, and the improvement of related factors in serum and lymph was more obvious under the condition of 42 °C thermotherapy in vitro.
    Journal
    |
    preladenant (SCH 420814)